Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders

Astellas Pharma Inc. and Cullgen Inc. announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.